Alphatec Holdings (ATEC) Cash from Financing Activities (2010 - 2026)
Alphatec Holdings (ATEC) reported Cash from Financing Activities of -$1.8 million for Q1 2026, down 105.77% on a YoY basis from $30.8 million in Q1 2025, and down 961.17% sequentially from $206000.0 in Q4 2025.
Alphatec Holdings (ATEC) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Alphatec Holdings (ATEC) has 17 years of Cash from Financing Activities data on file, last reported at -$1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 105.77% year-over-year to -$1.8 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 102.75% YoY), and the FY2025 full-year result was $30.0 million, down 46.59% from the prior year.
- Cash from Financing Activities slipped to -$1.8 million in Q1 2026, from $206000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $151.6 million in Q4 2023 to a low of -$4.4 million in Q1 2024.
- A 5-year average of $27.8 million and a median of $3.2 million in 2024 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 14862.59% in 2023 and sank 119.61% in 2025, its largest moves.
- Tracing ATEC's Cash from Financing Activities over 5 years: stood at $1.0 million in 2022, then soared by 14862.59% to $151.6 million in 2023, then slumped by 66.59% to $50.6 million in 2024, then plunged by 99.59% to $206000.0 in 2025, then tumbled by 961.17% to -$1.8 million in 2026.
- Business Quant data shows ATEC's Cash from Financing Activities at -$1.8 million in Q1 2026, $206000.0 in Q4 2025, and -$1.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Alphatec Holdings | 1.26 Bn | 1.12 Bn | 136.48 Mn | -1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.77 Mn |
| Mar 31, 2026 | -1.77 Mn |
| Dec 31, 2025 | 206,000.00 |
| Dec 31, 2025 | 206,000.00 |
| Sep 30, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 366,000.00 |
| Mar 31, 2025 | 30.76 Mn |
| Mar 31, 2025 | 30.76 Mn |
| Dec 31, 2024 | 50.64 Mn |
| Dec 31, 2024 | 50.64 Mn |
| Sep 30, 2024 | 6.69 Mn |
| Sep 30, 2024 | 6.69 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | -4.37 Mn |
| Mar 31, 2024 | -4.37 Mn |
| Dec 31, 2023 | 151.57 Mn |
| Dec 31, 2023 | 151.57 Mn |